A Double-Blind Trial of ??9-Tetrahydrocannabinol in Primary Anorexia Nervosa

Gross, Howard A.; Ebert, Michael H.; Faden, Vivian B.; Goldberg, Solomon C.; Kaye, Walter H.; Caine, Eric D.; Hawks, Richard L.; Zinberg, Norman E.

doi:10.1097/00004714-198306000-00004

Cited by 120 publications

(50 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These results support the idea that a pharmacological manipulation of the endocannabinoid tone might be beneficial in both patients with AN and BED. In this regard, it is worth mentioning that a previous attempt to potentiate the endocannabinoid transmission by delta 9-tetrahydrocannabinol administration in AN patients showed no therapeutic benefit (Gross et al, 1983); this failure may be tentatively understood in the light of the present findings. Conversely, phase III clinical trials indicate that the CB 1 antagonist rimonabant s is able to reduce BW in obese individuals, and likewise it is possible to predict future similar studies on the use of this compound also to correct other EDs.…”

Section: Discussionmentioning

confidence: 55%

Blood Levels of the Endocannabinoid Anandamide are Increased in Anorexia Nervosa and in Binge-Eating Disorder, but not in Bulimia Nervosa

Monteleone

Matías

Martiadis

et al. 2005

Neuropsychopharmacol

243

149

View full text Add to dashboard Cite

The endocannabinoid system, consisting of two cannabinoid receptors (CB 1 and CB 2 ) and the endogenous ligands anandamide (arachidonoylethanolamide (AEA)) and 2-arachidonoylglycerol (2-AG), has been shown to control food intake in both animals and humans, modulating either rewarding or quantitative aspects of the eating behavior. Moreover, hypothalamic endocannabinoids seem to be part of neural circuitry involved in the modulating effects of leptin on energy homeostasis. Therefore, alterations of the endocannabinoid system could be involved in the pathophysiology of eating disorders, where a deranged leptin signalling has been also reported. In order to verify this hypothesis, we measured plasma levels of AEA, 2-AG, and leptin in 15 women with anorexia nervosa (AN), 12 women with bulimia nervosa (BN), 11 women with binge-eating disorder (BED), and 15 healthy women. Plasma levels of AEA resulted significantly enhanced in both anorexic and BED women, but not in bulimic patients. No significant change occurred in the plasma levels of 2-AG in all the patients' groups. Moreover, circulating AEA levels were significantly and inversely correlated with plasma leptin concentrations in both healthy controls and anorexic women. These findings show for the first time a derangement in the production of the endogenous cannabinoid AEA in drug-free symptomatic women with AN or with BED. Although the pathophysiological significance of this alteration awaits further studies to be clarified, it suggests a possible involvement of AEA in the mediation of the rewarding aspects of the aberrant eating behaviors occurring in AN and BED.

show abstract

Section: Discussionmentioning

confidence: 55%

Blood Levels of the Endocannabinoid Anandamide are Increased in Anorexia Nervosa and in Binge-Eating Disorder, but not in Bulimia Nervosa

Monteleone

Matías

Martiadis

et al. 2005

Neuropsychopharmacol

243

149

View full text Add to dashboard Cite

show abstract

“…Results of a 4-week randomized, double-blind study of 11 patients with AN that compared oral THC with diazepam showed no benefit of THC on caloric intake, daily weight gain, or psychological symptoms. 26 In addition, THC was associated with negative side effects such as paranoia, sleep disturbance, and interpersonal sensitivity. A number of patients actually dropped out of the study due to the side effects they were experiencing.…”

Section: Tetrahydrocannabinol (Thc)mentioning

confidence: 99%

Pharmacologic treatment of anorexia nervosa: Where do we go from here?

Attia

Schroeder

2005

Int. J. Eat. Disord.

View full text Add to dashboard Cite

“…Unfortunately, there are only two small trials assessing cannabinoid treatment in AN [85]. The former involved 11 AN patients in a 4-week crossover trial and THC treatment resulted in increased sleep disturbances and interpersonal sensitivity, whereas there was no significant effect on weight gain [97]. Unfortunately, this study raised several concerns given it was an inpatient study and the occasional tube feeding was used.…”

Section: Therapeutic Use Of Cannabinoid Drugs In Eating Disordersmentioning

confidence: 99%

The role of endocannabinoids in the control of eating disorders

Milano¹,

Tecce²,

Capasso³

2017

Dis Disord

View full text Add to dashboard Cite

Eating Disorder (ED) is a syndrome characterized by persistent alteration of eating behavior and the conditions that cause an insufficient ingestion and/or adsorption of foods. There are three different ED diseases: Anorexia Nervosa (AN), Bulimia Nervosa (BN) and Binge Eating Disorders (BED). ED are complex conditions that arise from a combination of long-standing behavioral, emotional, psychological, interpersonal, and social factors. The neuronal circuits that control the ingestion of food are mainly related to catecholaminergic, serotoninergic and peptidergic systems. In this respect, while serotonin, dopamine and prostaglandin promote the ingestion of food, by contrast, neuropeptide Y, norepinephrine, GABA and opioid peptides inhibit food ingestion thus causing the occurrence of ED. The drugs mainly used in the treatment of ED are antidepressants such as selective serotonin reuptake inhibitors and tricyclic antidepressant. Additionally, mood stabilizers (lithium), anxiolytics, serotonin and noradrenalin reuptake inhibitors and antipsychotic drugs are often used in the treatment of ED.Several studies indicate that the endocannabinoid system is involved in ED supporting the idea that the cannabinoid signaling system is a key modulatory element in the activity in the brain area associated with ED.

show abstract

A Double-Blind Trial of ??9-Tetrahydrocannabinol in Primary Anorexia Nervosa

Cited by 120 publications

References 0 publications

Blood Levels of the Endocannabinoid Anandamide are Increased in Anorexia Nervosa and in Binge-Eating Disorder, but not in Bulimia Nervosa

Blood Levels of the Endocannabinoid Anandamide are Increased in Anorexia Nervosa and in Binge-Eating Disorder, but not in Bulimia Nervosa

Pharmacologic treatment of anorexia nervosa: Where do we go from here?

The role of endocannabinoids in the control of eating disorders

Contact Info

Product

Resources

About